Ptc Therapeutics Stock Buy Hold or Sell Recommendation
| PTCT Stock | USD 51.82 2.15 4.33% |
Given the investment horizon of 90 days and your complete indifference towards market risk, our recommendation regarding PTC Therapeutics is 'Strong Buy'. A buy or sell recommendation is an automated directive regarding whether to purchase or sell PTC Therapeutics given historical horizon and risk tolerance. When we issue a 'buy' or 'sell' recommendation for PTC Therapeutics, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out PTC Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For more information on how to buy PTC Stock please use our How to Invest in PTC Therapeutics guide. Note, we conduct extensive research on individual companies such as PTC and provide practical buy, sell, or hold advice based on investors' constraints. PTC Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
PTC |
Execute PTC Therapeutics Buy or Sell Advice
The PTC recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on PTC Therapeutics. Macroaxis does not own or have any residual interests in PTC Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute PTC Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Buy
Market Performance | Good | Details | |
Volatility | Very steady | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Impartial | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
PTC Therapeutics Trading Alerts and Improvement Suggestions
| PTC Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 937.82 M. Net Loss for the year was (626.6 M) with profit before overhead, payroll, taxes, and interest of 299.37 M. | |
| PTC Therapeutics currently holds about 288.43 M in cash with (158.42 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.01. | |
| Over 97.0% of the company shares are owned by institutional investors | |
| Latest headline from gurufocus.com: PTC Therapeutics Inc Announces Upcoming Conference Call for 2024 Financial Results |
PTC Therapeutics Returns Distribution Density
The distribution of PTC Therapeutics' historical returns is an attempt to chart the uncertainty of PTC Therapeutics' future price movements. The chart of the probability distribution of PTC Therapeutics daily returns describes the distribution of returns around its average expected value. We use PTC Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of PTC Therapeutics returns is essential to provide solid investment advice for PTC Therapeutics.
| Mean Return | 0.30 | Value At Risk | -3.75 | Potential Upside | 6.61 | Standard Deviation | 3.60 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of PTC Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
PTC Stock Institutional Investors
The PTC Therapeutics' institutional investors refer to entities that pool money to purchase PTC Therapeutics' securities or originate loans. These institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds.
| Shares | D. E. Shaw & Co Lp | 2024-09-30 | 1.4 M | Franklin Resources Inc | 2024-09-30 | 1.4 M | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 1.2 M | Jpmorgan Chase & Co | 2024-09-30 | 1.1 M | Blackstone Inc | 2024-09-30 | 1.1 M | Fmr Inc | 2024-09-30 | 1.1 M | Goldman Sachs Group Inc | 2024-09-30 | 822.4 K | Nuveen Asset Management, Llc | 2024-09-30 | 804.2 K | Tang Capital Management Llc | 2024-09-30 | 700 K | Vanguard Group Inc | 2024-09-30 | 9.1 M | Blackrock Inc | 2024-09-30 | 8 M |
PTC Therapeutics Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Capital Expenditures | 56.0M | 85.3M | 152.5M | 120.6M | 138.7M | 145.6M | |
| End Period Cash Flow | 216.3M | 197.2M | 295.9M | 610.3M | 701.8M | 736.9M | |
| Change In Cash | (79.2M) | (19.1M) | 98.7M | 314.4M | 361.5M | 379.6M | |
| Free Cash Flow | (250.0M) | (336.7M) | (509.1M) | (279.0M) | (251.1M) | (238.6M) | |
| Depreciation | 84.9M | 64.1M | 128.8M | 236.6M | 272.1M | 285.7M | |
| Other Non Cash Items | 46.1M | 128.3M | 82.8M | 151.3M | 174.0M | 182.7M | |
| Net Income | (438.2M) | (523.9M) | (559.0M) | (626.6M) | (563.9M) | (535.7M) | |
| Change To Inventory | 1.8M | 1.8M | (6.7M) | (8.2M) | (7.4M) | (7.0M) | |
| Investments | (505.6M) | 304.5M | 442.6M | (49.9M) | (57.4M) | (54.5M) | |
| Change Receivables | 11.5M | (10.5M) | (45.0M) | (48.5M) | (43.6M) | (41.4M) | |
| Change To Netincome | 97.8M | 65.1M | 230.4M | 113.8M | 130.8M | 79.0M |
PTC Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to PTC Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that PTC Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a PTC stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.29 | |
β | Beta against Dow Jones | 0.66 | |
σ | Overall volatility | 3.55 | |
Ir | Information ratio | 0.08 |
PTC Therapeutics Volatility Alert
PTC Therapeutics currently demonstrates below-average downside deviation. It has Information Ratio of 0.08 and Jensen Alpha of 0.29. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure PTC Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact PTC Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.PTC Therapeutics Fundamentals Vs Peers
Comparing PTC Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze PTC Therapeutics' direct or indirect competition across all of the common fundamentals between PTC Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as PTC Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of PTC Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing PTC Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare PTC Therapeutics to competition |
| Fundamentals | PTC Therapeutics | Peer Average |
| Return On Equity | -77.4 | -0.31 |
| Return On Asset | -0.0515 | -0.14 |
| Profit Margin | (0.50) % | (1.27) % |
| Operating Margin | (0.26) % | (5.51) % |
| Current Valuation | 3.38 B | 16.62 B |
| Shares Outstanding | 77.13 M | 571.82 M |
| Shares Owned By Insiders | 2.57 % | 10.09 % |
| Shares Owned By Institutions | 97.43 % | 39.21 % |
| Number Of Shares Shorted | 4.16 M | 4.71 M |
| Price To Earning | (5.67) X | 28.72 X |
| Price To Book | 1,743 X | 9.51 X |
| Price To Sales | 4.44 X | 11.42 X |
| Revenue | 937.82 M | 9.43 B |
| Gross Profit | 299.37 M | 27.38 B |
| EBITDA | (330.34 M) | 3.9 B |
| Net Income | (626.6 M) | 570.98 M |
| Cash And Equivalents | 288.43 M | 2.7 B |
| Cash Per Share | 4.01 X | 5.01 X |
| Total Debt | 2.23 B | 5.32 B |
| Current Ratio | 1.23 X | 2.16 X |
| Book Value Per Share | (13.70) X | 1.93 K |
| Cash Flow From Operations | (158.42 M) | 971.22 M |
| Short Ratio | 6.87 X | 4.00 X |
| Earnings Per Share | (5.94) X | 3.12 X |
| Price To Earnings To Growth | 0.81 X | 4.89 X |
| Target Price | 61.71 | |
| Number Of Employees | 988 | 18.84 K |
| Beta | 0.62 | -0.15 |
| Market Capitalization | 4 B | 19.03 B |
| Total Asset | 1.9 B | 29.47 B |
| Retained Earnings | (3.28 B) | 9.33 B |
| Working Capital | 615.53 M | 1.48 B |
| Current Asset | 355.95 M | 9.34 B |
Note: Acquisition by Eric Pauwels of 55000 shares of PTC Therapeutics at 46.54 subject to Rule 16b-3 [view details]
PTC Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as PTC . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About PTC Therapeutics Buy or Sell Advice
When is the right time to buy or sell PTC Therapeutics? Buying financial instruments such as PTC Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having PTC Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Health Care ETFs Thematic Idea Now
Health Care ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Health Care ETFs theme has 47 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Health Care ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for PTC Stock Analysis
When running PTC Therapeutics' price analysis, check to measure PTC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PTC Therapeutics is operating at the current time. Most of PTC Therapeutics' value examination focuses on studying past and present price action to predict the probability of PTC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PTC Therapeutics' price. Additionally, you may evaluate how the addition of PTC Therapeutics to your portfolios can decrease your overall portfolio volatility.